Press Releases

Date Title
7/6/22 Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
7/5/22 Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET
6/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/23/22 Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
6/2/22 Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors
6/2/22 Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
5/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/5/22 Sarepta Therapeutics Launches Inaugural LGMD Grant Award Program
5/5/22 Sarepta Therapeutics lanza el programa inaugural de concesión de subvenciones para la LGMD
5/4/22 Sarepta Therapeutics Announces First Quarter 2022 Financial Results and Recent Corporate Developments
Displaying 81 - 90 of 813